Idelalisib (Zydelig▼): interim measures following signal of serious infection and deaths related to infection found in clinical trials

There are new interim treatment recommendations for idelalisib for chronic lymphocytic leukaemia and follicular lymphoma in light of new findings from clinical trials outside its currently authorised drug combinations or indicated populations.